Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Summary: Potent incretin‐based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin‐based obesity treatments, once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide. The treatment effect, shown as placebo‐subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild‐to‐moderate severity and mostly gastrointestinal, which was more frequent during the dose‐titration period and leveled off during the treatment period. This emphasizes that once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well‐tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“12,13 16 Exercise interventions typically result in modest weight losses of about 0 to 4 kg but with reduced fat mass and preserved lean mass, improving body composition.”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 7×
“Since weight loss with semaglutide seems to continue for at least a year, 42,43 studies of shorter duration could underestimate the treatment efficacy.”
BackgroundMethodInfluentialProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 6×
“The included studies were all phase 3 randomized controlled trials investigating either the effect of subcutaneous semaglutide (five studies 29,42,43,55,56 ) or tirzepatide (two studies 57,58 ).”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0310-7 · Cited by 1,966 · cited 1×
“46,47 Therefore, we conducted a systematic review and meta-analysis to assess the efficacy and safety of subcutaneous semaglutide and tir-zepatide in the doses approved for obesity on body weight and waist circumference reduction in people with overweight or obesity without diabetes, treated for a…”
MethodGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“18,19 Weight loss decreases energy expenditure, increases sedentary behavior, and may affect appetite 20,21 with observations of increased appetite at least a year after diet-induced weight loss in some studies, 22 – 24 which makes sustained weight loss difficult.”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 1×
“69 Oral semaglutide has been found effective for treating type 2 diabetes, 70,71 and now also for obesity.”
BackgroundWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 2×
“29,42,43,55,57,58 In STEP TEENS, 56 participants were included if they had a BMI in the 95th percentile or higher or a BMI in the 85th percentile or higher and at least one weight-related comorbidity.”
BackgroundWeight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096 · cited 1×
“However, increased physical activity can preserve lean mass during weight loss, 64,65 and obesity medications are usually approved by medicines agencies as an adjunct to recommendations of lifestyle modifications.”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · cited 5×
“The majority of the included studies, the STEP trials, investigated the effect of subcutaneous semaglutide 2.4 mg once-weekly for 68 weeks (STEP 1, 42 STEP 3, 55 STEP 8, 29 and STEP TEENS 56 ) or 104 weeks (STEP 5 43 ) for the treatment of overweight or obesity.”
BackgroundInfluentialWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730 · cited 4×
“29,42,43,55,57,58 In STEP TEENS, 56 participants were included if they had a BMI in the 95th percentile or higher or a BMI in the 85th percentile or higher and at least one weight-related comorbidity.”
BackgroundInfluentialPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 1×
“69 Oral semaglutide has been found effective for treating type 2 diabetes, 70,71 and now also for obesity.”
BackgroundHealthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 2×
“18,19 Weight loss decreases energy expenditure, increases sedentary behavior, and may affect appetite 20,21 with observations of increased appetite at least a year after diet-induced weight loss in some studies, 22 – 24 which makes sustained weight loss difficult.”
BackgroundSelf-citationDavies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Lee, D. H., Keum, N., Hu, F. B., Orav, E. J., Rimm, E. B., Willett, W. C., & Giovannucci, E. L. (2018) · BMJ · doi:10.1136/bmj.k2575 · Cited by 486 · cited 1×
“46,47 Therefore, we conducted a systematic review and meta-analysis to assess the efficacy and safety of subcutaneous semaglutide and tir-zepatide in the doses approved for obesity on body weight and waist circumference reduction in people with overweight or obesity without diabetes, treated for a…”
MethodDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442 · cited 6×
“The included studies were all phase 3 randomized controlled trials investigating either the effect of subcutaneous semaglutide (five studies 29,42,43,55,56 ) or tirzepatide (two studies 57,58 ).”
BackgroundInfluentialKnop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Bellicha, A., van Baak, M. A., Battista, F., Beaulieu, K., Blundell, J. E., Busetto, L., Carraça, E. V., Dicker, D., Encantado, J., Ermolao, A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13256 · Cited by 375 · cited 1×
“17 Importantly, exercise can effectively maintain diet-induced weight loss and improve body composition for at least 1 year.”
BackgroundEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288 · cited 1×
“59 The STEP 1 trial by Wilding et al. 42 All included trials used double-blinding for their placebo-controlled analyses.”
MethodJensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207 · cited 2×
“75,66 The present review has several strengths.”
BackgroundSelf-citationSandsdal, R. M., Juhl, C. R., Jensen, S. B. K., Lundgren, J. R., Janus, C., Blond, M. B., Rosenkilde, M., Bogh, A. F., Gliemann, L., Jensen, J.-E. B., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01765-z · Cited by 195
Self-citationAstbury, N. M., Aveyard, P., Nickless, A., Hood, K., Corfield, K., Lowe, R., & Jebb, S. A. (2018) · BMJ · doi:10.1136/bmj.k3760 · Cited by 155
Singh, A. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1698291 · Cited by 130
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationTan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83 · cited 1×
“44,45 Furthermore, while the body mass index (BMI, body weight [kg] divided by the squared height [m]) is useful to define obesity at a population level, BMI does not consider body composition or fat distribution.”
BackgroundGao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Zhong, P., Zeng, H., Huang, M., Fu, W., & Chen, Z. (2022) · Endocrine · doi:10.1007/s12020-021-02945-1 · Cited by 74 · cited 3×
“Therefore, the analyses differ from previously reported meta-analyses by not including once-daily semaglutide, 38 – 40 studies with a duration of less than a year, 38,41 and the STEP 4 study, 60 in which the control group switched to placebo after a 20-week semaglutide treatment phase.”
BackgroundResultInfluentialInvestigation of the long-term sustainability of changes in appetite after weight loss
Nymo, S., Coutinho, Sr., Eknes, P., Vestbostad, I., Rehfeld, J., Truby, H., Kulseng, B., & Martins, C. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0119-9 · Cited by 68 · cited 1×
“18,19 Weight loss decreases energy expenditure, increases sedentary behavior, and may affect appetite 20,21 with observations of increased appetite at least a year after diet-induced weight loss in some studies, 22 – 24 which makes sustained weight loss difficult.”
BackgroundJensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32307-y · Cited by 42
Self-citationArastu, N., Cummins, O., Uribe, W., & Nemec, E. C. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01428-1 · Cited by 33
Research works printed but not linked: 20
- 10.1186/s12889‐021‐12449‐2 · DOI · Paper page
- 10.1093/humrep/deac096 · DOI
- 10.1038/s41366‐021‐00788‐4 · DOI · Paper page
- 10.1093/tbm/ibab110 · DOI
- 10.1093/jn/nxz296 · DOI · Paper page
- 10.1007/s40264‐019‐00812‐7 · DOI
- 10.4314/ahs.v19i3.35 · DOI · Paper page
- 10.1016/S0140‐6736(18)31773‐2 · DOI · Paper page
- 10.1080/00325481.2022.2147326 · DOI · Paper page
- 10.1016/s0140‐6736(21)01324‐6 · DOI · Paper page
- 10.1002/oby.23612 · DOI · Paper page
- 10.15605/jafes.037.02.14 · DOI · Paper page
- 10.1038/s41591‐022‐02026‐4 · DOI · Paper page
- 10.1371/journal.pone.0285197 · DOI · Paper page
- 10.1002/9781119536604 · DOI · Paper page
- Veritas Health Innovation.Covidence systematic review software. Accessed November 22 2023.www.covidence.org
- Cochrane Training. Review Manager (RevMan). Accessed November 22 2023.https://training.cochrane.org/online‐learning/core‐software/revman
- 10.1001/jama.2021.3224 · DOI · Paper page
- 10.1038/oby.2012.70 · DOI · Paper page
- 10.1056/nejmoa066254 · DOI · Paper page
Cited by
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Self-citationCengiz, A., Wu, C. C., & Lawley, S. D. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16229 · Cited by 20
Brain Activity Associated with Breakthrough Food Preoccupation in an Individual on Tirzepatide
Choi, W., Nho, Y.-H., Qiu, L., Chang, A., Campos, G., Seilheimer, R. L., Wilent, W. B., Bakalov, D., Firdous, N., Kerr, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04035-5 · Cited by 10
Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
Wu, C. C., Cengiz, A., & Lawley, S. D. (2025) · Obesity · doi:10.1002/oby.24302 · Cited by 9
“Meta-analyses of randomized controlled trials have indicated that semaglutide and tirzepatide facilitate an average placebo-adjusted body weight (BW) loss of 15.0% and 19.2% [ 1], respectively, compared with the 5% to 10% of older generation antiobesity medications (AOMs) [ 2].”
InfluentialJensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
“More effective pharmacotherapies are now available, reaching weight losses exceeding 20% [17].”
Self-citation
Metadata
- Authors
- Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2024-03-11
- Volume
- 25
- Issue
- 5
- Pages
- e13717-e13717
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W4392658789
- Cited by
- 46
- References
- 49
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Helsefonden (20‐B‐0389)
- Novo Nordisk Fonden (NNF22SA0079901, NNF16OC0019968, NNF15CC0018486, NNF23OC0084305)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.